“Eli Lilly Might Be the Next Stock I Buy | LLY Stock Analysis”
Eli Lilly is a buy; the stock is undervalued and expected to rise by about 30% in the next 12-18 months.
Although Eli Lilly was the second company to introduce oral pills for weight loss treatments, it had already begun to acquire a significant market share. The company boasted a market share exceeding 30% in new initiations within the oral GLP-1 drug sector , identifying more than 36,000 people.